Evidence map›Paper›PMID 39556280›Full record

ArticleMolecular biotechnology2025

N6-Methyladenosine Modification of PERP by RBM15 Enhances the Tumorigenesis of Lung Adenocarcinoma via p53 Signaling Pathway.

Ruiying Li, Xiaochuang Xia, Wenping Chen, Hongmin Wang, Lunda Feng, Zhouyi Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. RBM15-mediated mFrontiers in cell and developmental biology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruiying Li *Department of Geriatrics, Huanggang Central Hospital, No.126, Huangzhou District, Huanggang, 438000, Hubei, China.
Xiaochuang Xia *Department of Cardiovascular Medicine, Huanggang Central Hospital, Huanggang 438000, Hubei, China.
Wenping Chen *Department of Endocrinology, Huanggang Central Hospital, Huanggang 438000, Hubei, China.
Hongmin WangDepartment of Rehabilitation Medicine, Huanggang Central Hospital, Huanggang 438000, Hubei, China.
Lunda FengDepartment of Rehabilitation Medicine, Huanggang Central Hospital, Huanggang 438000, Hubei, China.
Zhouyi WangDepartment of Geriatrics, Huanggang Central Hospital, No.126, Huangzhou District, Huanggang, 438000, Hubei, China. wzy162202@163.com.ORCID http://orcid.org/0009-0006-2183-9042

Funding

Hubei University of Science and Technology 2022YKY32
6 · The paper itself

Abstract

The promotive effect of P53 apoptosis effector related to PMP-22 (PERP) on lung adenocarcinoma (LUAD) has been confirmed. However, the N6-methyladenosine (m6A) modification of PERP to regulate LUAD progression have not been revealed. Bioinformatic analysis predicted the mechanism of PERP interacting with RBM15 and p53 pathway using GEPIA and The Cancer Genome Atlas (TCGA) databases. The qRT-PCR, cell function experiments, and western blotting were applied to further confirm the function and mechanism of PERP and RBM15 in LUAD cells. Methylated RNA immunoprecipitation (MeRIP) and mRNA stability assays were used to reveal the interaction between PERP and RBM15 in LUAD cells. PERP with high expression in LUAD showed the poor survival. Silencing PERP prevented LUAD cells to proliferate, migrate, and invade via activating p53 pathway, whereas overexpressing PERP showed the opposite effect on LUAD cells. Mechanistically, RBM15 overexpression could promote PERP m6A modification to enhance the PERP mRNA stability. In addition, RBM15 overexpression leading to LUAD cell malignancy was reversed by PERP knockdown. This study reveals that the m

Indexed as

Adenocarcinoma of LungAdenosineLung NeoplasmsMembrane ProteinsRNA-Binding ProteinsTumor Suppressor Protein p53CarcinogenesisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansRNA StabilitySignal TransductionAdenosineMembrane ProteinsN-methyladenosineRNA-Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Lung adenocarcinomaN6-methyladenosineP53PERPRBM15

Identifiers

PMID39556280

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.